CAPTRUST Financial Advisors
NAUT icon

CAPTRUST Financial Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.6K Sell
34,000
-3
-0% -$8 ﹤0.01% 3106
2026
Q1 		$132K Sell
34,003
-8
-0% -$20 ﹤0.01% 2768
2025
Q4 		$66.3K Buy
+34,011
New +$55.8K ﹤0.01% 2655

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

CAPTRUST Financial Advisors's NAUT Position: Q2 2026 in Review

CAPTRUST Financial Advisors reduced its Nautilus Biotechnolgy (NAUT) stake by 0.01% in Q2 2026, selling an estimated $8 and leaving 34,000 shares worth $63.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3106.

CAPTRUST Financial Advisors first reported a position in NAUT in Q4 2025 and has held it in 3 quarters since. The position peaked at $132K in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • CAPTRUST Financial Advisors held 34,000 shares of Nautilus Biotechnolgy worth $63.6K as of Q2 2026.
  • CAPTRUST Financial Advisors sold 3 Nautilus Biotechnolgy shares in Q2 2026, an estimated $8.
  • Nautilus Biotechnolgy made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3106 holding.
  • CAPTRUST Financial Advisors first reported a position in Nautilus Biotechnolgy in Q4 2025 and has held it in 3 quarters since.
  • CAPTRUST Financial Advisors's Nautilus Biotechnolgy position peaked at $132K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.